Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status

Launched by YUNNAN CANCER HOSPITAL · Nov 27, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging technology designed to help doctors accurately identify breast cancer tissue and assess whether cancer has spread to nearby sentinel lymph nodes (SLN) during surgery. By using a special fluorescent probe that lights up cancerous cells, the goal is to improve the precision of breast-conserving surgeries. This means patients may have fewer follow-up surgeries and a better understanding of their cancer's spread, which can lead to less complicated treatments.

To participate in this trial, women aged 18 to 75 who have a breast lump that doctors believe can be removed surgically may be eligible. Participants should be in good health for surgery and able to provide consent. If you join the study, you will receive the standard care for your breast cancer while also undergoing this new imaging process during your surgery. The researchers will compare the results from this imaging with traditional lab tests to ensure accuracy. This trial is currently recruiting participants, and your involvement could help advance breast cancer treatment for future patients.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Adult patients between 18-75 years of age
• • Female
• • Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment
• • Good operative candidate
• • Subject capable of giving informed consent and participating in the process of consent
• Exclusion Criteria:
• • Patients unable to participate in the consent process
• • Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc
• • Other conditions that the researcher considers inappropriate to participate in the study